SMG9 Serves as an Oncogene to Promote the Tumor Progression via EMT and Wnt/ β-Catenin Signaling Pathway in Hepatocellular Carcinoma
Conclusions: SMG9 may serve as a potential novel prognostic biomarker and therapeutic target in HCC patients.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Databases & Libraries | Drugs & Pharmacology | Genetics | Hepatocellular Carcinoma | Liver | Liver Cancer | Study | Urology & Nephrology